Production and activation of matrix metalloprotease-9 (MMP-9) by HL-60 promyelocytic leukemia cells.

Human promyelocytic HL-60 cells have been used as a model of acute leukemia to investigate the expression and the regulation of matrix metalloproteases (MMPs), known to contribute to the degradation of extracellular matrix components. As shown by gelatin zymography, HL-60 cells constitutively released significant amounts of proMMP-9 (92 kDa) and moderate amounts of proMMP-2 (72 kDa). Furthermore, casein zymography confirmed the presence of serine proteases in the form of pro-urokinase. Activation of proMMP-9 was dependent on the plasminogen activator/plasmin (PA/plasmin) system and was inhibited by aprotinin. MMP-9 was only detected in cellular extracts or conditioned media incubated with HL-60 cells, indicating that cells are essential to the activation process. Addition of plasminogen increased by 3-fold the basal invasive rate of these cells across a matrigel layer (2.1% versus 0.7% in control cells after 4 h of incubation). Taken together, these results indicate that HL-60 cells exhibit an autocrine activation mechanism of proMMP-9 via the PA/plasmin system and that activation of proMMP-9 increases their invasive potential.

[1]  J. Wilson.  Adhesive interactions in hemopoiesis. , 1997, Acta haematologica.

[2]  L. Zanetta,et al.  Control of type IV collagenase activity by components of the urokinase–plasmin system: a regulatory mechanism with cell‐bound reactants , 1997, The EMBO journal.

[3]  J. Foidart,et al.  Involvement of PA/plasmin system in the processing of pro‐MMP‐9 and in the second step of pro‐MMP‐2 activation , 1997, FEBS letters.

[4]  A. Gulino,et al.  Identification of plasminogen in Matrigel and its activation by reconstitution of this basement membrane extract. , 1996, BioTechniques.

[5]  K. Dittmann,et al.  HL-60 leukemia cells produce an autocatalytically truncated form of matrix metalloproteinase-9 with impaired sensitivity to inhibition by tissue inhibitors of metalloproteinases. , 1996, Leukemia.

[6]  H. Sato,et al.  Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase. , 1996, Cancer research.

[7]  Hong Li,et al.  Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells , 1996, FEBS letters.

[8]  Michael S. Pepper,et al.  Membrane proteases in focus , 1994, Nature.

[9]  M. Janiak,et al.  Use of the Matrigel-based assay to measure the invasiveness of leukemic cells. , 1994, Experimental hematology.

[10]  P. Petrides,et al.  Regulation of 92-kD gelatinase release in HL-60 leukemia cells: tumor necrosis factor-alpha as an autocrine stimulus for basal- and phorbol ester-induced secretion. , 1994, Blood.

[11]  J. Foidart,et al.  Evaluation of matrix metalloproteinases and serine proteases activities in three B16 melanoma cell lines with distinct tumorigenic potential. , 1994, Anticancer research.

[12]  F. Blasi.  Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness , 1993 .

[13]  U. Thorgeirsson,et al.  Studies on the ability of 65-kDa and 92-kDa tumor cell gelatinases to degrade type IV collagen. , 1990, The Journal of biological chemistry.

[14]  U. Moll,et al.  Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells. , 1990, Cancer research.

[15]  J. Hoidal,et al.  Alveolar epithelial cell plasminogen activator. Characterization and regulation. , 1990, The Journal of biological chemistry.

[16]  B. Martin,et al.  Differentiation of HL-60 Promyelocytic Leukemia Cells: A Member of the Collagenase Family of Enzymes , 1990 .

[17]  B. Alving,et al.  Stimulated production of urokinase and plasminogen activator inhibitor-2 by the human promyelocytic leukemia cell line HL-60. , 1988, Thrombosis research.

[18]  Y. Iwamoto,et al.  Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. , 1988, Cancer research.

[19]  J. Foidart,et al.  Interactions between fibroblasts and a reconstituted basement membrane matrix. , 1987, The Journal of investigative dermatology.

[20]  Y Iwamoto,et al.  A rapid in vitro assay for quantitating the invasive potential of tumor cells. , 1987, Cancer research.

[21]  E. Freireich.  Charles F. Kettering prize. Acute leukemia. A prototype of disseminated cancer , 1984 .

[22]  L. Liotta,et al.  Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells – role in metastasis , 1982, International journal of cancer.

[23]  R. Stephens,et al.  Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator , 1981, International journal of cancer.

[24]  E. Dowdle,et al.  Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. , 1980, Analytical biochemistry.

[25]  Suraiya Rasheed,et al.  Characterization of a newly derived human sarcoma cell line (HT‐1080) , 1974, Cancer.

[26]  A. Vaheri,et al.  Plasminogen activation on tumor cell surface and its involvement in human leukemia. , 1996, Advances in cancer research.

[27]  J. Foidart,et al.  Evaluation of in vitro reconstituted basement membrane assay to assess the invasiveness of tumor cells. , 1992, Invasion & metastasis.

[28]  J. Foidart,et al.  Invasion of reconstituted basement membrane matrix is not correlated to the malignant metastatic cell phenotype. , 1991, Cancer research.